Currently approved antiplatelet treatment strategies have proved successful for reducing cardiovascular adverse events in patients with CAD. However, despite the use of recommended antiplatelet treatment strategies, the presence of DM has been consistently associated with a negative impact on outcomes and a high rate of adverse cardiovascular events continue to occur in patients with DM. The elevated prevalence of low response to standard oral antiplatelet agents contribute to these impaired outcomes. Thus, the search for more potent antiplatelet treatment strategies is warranted in high-risk patients, such as those with DM. The present manuscript provides an overview on the current status of knowledge on currently available antiplatelet agents, focusing on the benefits and limitations of these therapies in DM patients, and evaluating the potential role of new antithrombotic agents and treatment strategies currently under development to overcome these limitations.
Introduction
The increasing worldwide prevalence of diabetes mellitus (DM), which is currently affecting more than 150 million people, mainly due to type 2 DM, has led to label this disease as a 'global pandemic'. 1, 2 The burden of cardiovascular disease among patients with DM is substantial and has been confirmed in large-scale surveys, such as the Euro Heart Survey, the 'Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE)' registry and the US-based National Registry of Myocardial Infarction, which showed a prevalence of diabetes of approximately 30% both in patients with stable coronary artery disease (CAD) and in those with acute coronary syndromes (ACSs), including non-ST-segment elevation acute coronary syndrome (NSTEACS) and ST-segment myocardial infarction (STEMI). [3] [4] [5] In fact, cardiovascular disease is the leading cause of morbidity and mortality in patients with DM, due mostly to the role played by CAD. 6 Of note, subjects with DM have a 2-4-fold increased risk of cardiovascular events than non-DM subjects, and 68% of deaths among DM patients over the age of 65 years are due to CAD. 7 Platelets play a key role in the development of atherosclerosis and its atherothrombotic complications. 8 Platelets available antiplatelet agents, focusing on the benefits and limitations of these therapies in DM patients, and evaluating the potential role of new antithrombotic agents and treatment strategies currently under development to overcome these limitations.
Currently approved antiplatelet therapies
Three different classes of antiplatet agents are currently approved for the treatment and prevention of recurrent ischaemic events in patients with CAD: cyclooxigenase-1 (COX-1) inhibitors (aspirin), adenosine diphosphate (ADP) P2Y 12 receptor antagonists (thienopyridines) and glycoprotein (GP) IIb/IIIa inhibitors. [22] [23] [24] This section provides insights on the benefits and limitations of these agents in patients with DM.
Aspirin
Aspirin is an irreversible inhibitor of COX-1, the enzyme that catalyses the synthesis of thromboxane A 2 (TXA 2 ) from arachidonic acid, by acetylation of the hydroxyl group of a serine residue at position 529 (Ser529). TXA 2 binds to thromboxane/prostaglandin endoperoxide (TP) receptors, resulting in changes in platelet shape and enhancement of recruitment and aggregation of platelets. Therefore, aspirin blocks platelet formation of TXA 2 and, as a result, diminishes platelet aggregation mediated by the TP receptors pathway. 25 The use of aspirin for primary prevention in DM patients is controversial. In 2007, the American Diabetes Association (ADA) and the American Heart Association (AHA) jointly recommended aspirin therapy (75-162 mg/day) for primary prevention in DM patients at increased cardiovascular risk, 26 while according to European guidelines aspirin was not recommended in this setting. 27 Among the trials that have evaluated the effect of aspirin for primary prevention of cardiovascular events, most of these were population based, [28] [29] [30] [31] [32] [33] while only three of them were focused specifically on DM patients. [34] [35] [36] Owing to the lack of consistency of the findings, a number of metaanalyses have been performed in order to reconcile the results obtained in the different trials, [37] [38] [39] [40] being of special interest the metaanalysis performed with individual patient-level data from the nine trials mentioned above by a group of experts of the ADA, AHA and the American College of Cardiology Foundation with the purpose of providing an expert consensus document. 40 Overall, the metaanalyses showed that aspirin appears to cause a modest size reduction in cardiovascular events [myocardial infarction (MI) and stroke], but current evidence is not conclusive to recommend its use as primary prevention in all patients with DM. 40 This has led to the most recent recommendation in the previously mentioned expert consensus document, in which lowdose (75-162 mg/day) aspirin use for primary prevention is recommended in DM patients at increased cardiovascular disease risk (men over age 50 years and women over age 60 years with a 10-year risk of cardiovascular events over 10%) and who are not at increased risk of bleeding. 40 The ongoing trials A Study of Cardiovascular Events iN Diabetes' (ASCEND; NCT00135226) and Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D; ISRCTN48110081) will provide further insights into the role of aspirin as a primary prevention measure in patients with DM.
Aspirin remains the antiplatelet drug of choice for secondary prevention of recurrent ischaemic events in patients with an atherothrombotic manifestation of CAD or undergoing percutaneous coronary intervention (PCI). [23] [24] [25] 41 The benefit of aspirin therapy in the setting of ACS has been consistently demonstrated since the earliest trials, including those evaluating NSTEACS [42] [43] [44] and STEMI. 45, 46 As per guidelines, aspirin must be given as promptly as possible, at an initial dose of 162-325 mg followed by a daily dose of 75-162 mg, 23, 24 which is also the recommended maintenance dose of aspirin for secondary prevention in DM patients with atherosclerotic disease. 41 Two large metaanalyses of secondary prevention trials performed by the Antithrombotic Trialists' Collaboration, involving 212,000 high-risk patients (with acute or previous vascular disease or some other predisposing condition implying an increased risk of occlusive vascular disease), supported the use of low-dose aspirin. 47, 48 These metaanalyses showed that the benefit of oral antiplatelet agents was consistent independently of DM status (38 vascular events were prevented for every 1,000 DM patients and 36 events for every 1,000 non-DM patients), even though the overall incidence of vascular events was much higher in DM patients. 47 Aspirin was the most commonly evaluated antiplatelet agent, at doses ranging from 75 to 325 mg daily. Importantly, the use of low-dose aspirin (75-150 mg/day) was found to be at least as effective as higher daily doses, while bleeding complications were diminished with the lower doses. 47, 48 The Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT/OASIS7; NCT00335452) trial included ACS patients (n=25,087) scheduled to undergo angiography that were randomised in a 2 � 2 facto-� 2 facto-2 factorial design to high or standard dose of clopidogrel for a month and in an open-label way to high (300-325 mg daily) versus low dose (75-100 mg daily) of aspirin. This trial was the first large-scale randomised study to compare highwith low-dose aspirin and no significant differences in efficacy among aspirin doses were found. However, a trend towards a higher rate of gastrointestinal bleeds in the highdose group was reported, although the bleeding rates can be considered relatively low (0.38% vs. 0.24%; p=0.051). 49 The results of this study in the DM subset regarding aspirin dosage have not yet been made available.
P2Y 12 receptor antagonists: thienopyridines
Thienopyridines (ticlopidine, clopidogrel and prasugrel) are non-direct, orally administered and irreversible platelet ADP P2Y 12 receptor inhibitors. ADP-induced effects on platelets are mediated by the P2Y 1 and P2Y 12 receptors, which are both required for aggregation, although P2Y 12 stimulation plays the principal role, leading to sustained platelet aggregation and stabilisation of the platelet aggregate. [50] [51] [52] Ticlopidine, a first-generation thienopyridine, was the first to be developed and approved for clinical use, although it was largely replaced by clopidogrel (a secondgeneration thienopyridine), which has a better safety profile. 53 In addition, clopidogrel achieves a faster onset on action through administration of a loading dose. 54 The Clopidogrel vs Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial compared the efficacy for secondary prevention of clopidogrel (75 mg daily) versus aspirin (325 mg daily) in a high-risk population (n=19,185) consisting of patients with a history of recent MI, recent ischaemic stroke or established peripheral artery disease. A reduction in the risk of ischaemic outcomes in the clopidogrel group was observed (5.32% vs. 5.83%; p=0.043). 55 The benefit of clopidogrel therapy was higher (15.6% vs. 17.7%; p=0.042) in DM patients, despite the increased incidence of ischaemic outcomes in this subgroup. The absolute reduction in events was highest among diabetic patients requiring insulin therapy. On the other hand, the reduction in the rates of ischaemic outcomes in patients without DM did not reach statistical significance. 56 The use of clopidogrel should be considered in very high-risk DM patients or as an alternative therapy in patients intolerant to aspirin. 41 The efficacy of dual antiplatelet treatment with aspirin and clopidogrel is well established and recommended in the guidelines for patients with ACS, including those with NSTEACS 23 and STEMI, and for patients undergoing PCI. 24 Several large-scale clinical trials have shown a clear benefit of clopidogrel in addition to aspirin for preventing recurrent ischaemic events, including stent thrombosis, when compared to aspirin alone. 18, [57] [58] [59] [60] [61] Table 1 summarises ACS/PCI trials comparing dual antiplatelet therapy with aspirin and a thienopyridine versus aspirin alone, highlighting the relative benefits in the overall population and in patients with DM.
The role of dual antiplatelet therapy with aspirin and clopidogrel for patients at high risk for ischaemic events, but not presenting with an ACS or undergoing PCI, was evaluated in the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management and Avoidance (CHARISMA; NCT00050817) trial. This trial included patients (n=15,603) with either clinically evident cardiovascular disease or multiple cardiovascular risk factors. In this study, concomitant treatment with clopidogrel and aspirin was not significantly more effective than aspirin alone in reducing the rates of cardiovascular death, MI or stroke (6.8% vs. 7.3%; p=0.22). 62 Consistently, no benefit of combined therapy was observed in patients with DM.
The efficacy of high versus standard dose of clopidogrel was evaluated in the CURRENT/OASIS7 trial, which included ACS patients (n=25,087) scheduled to undergo angiography within 72 h of hospital arrival. In the overall study population, no benefit was derived from the high-dose regimen. Nevertheless, in the subgroup of patients undergoing PCI (n=17,232), the high clopidogrel dose strategy diminished the rates of ischaemic outcomes [3.9% vs. 4.5%; hazard ratio (HR)=0.85; p=0.036) and reduced the risk of stent thrombosis by 30%, although it was at the expense of increased study-defined major bleedings. There were no differences in efficacy among the subset of patients with DM undergoing PCI [4.9% vs. 5.6%; HR=0.87 (0.66-1.15)]. 49 Prasugrel, as all thienopyridines, is a prodrug that requires hepatic biotransformation into its active metabolite to irreversibly block the P2Y 12 receptor. 63 This thirdgeneration thienopyridine has a faster onset of action than clopidogrel and reaches greater platelet inhibition due to a more efficient conversion into its active metabolite, with less interindividual variability in response, even compared with high-dose clopidogrel. 64 The efficacy and safety of prasugrel (60 mg loading dose followed by a 10 mg maintenance dose) versus clopidogrel therapy (300 mg loading dose followed by 75 mg daily maintenance dose) was evaluated in the randomised Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38; NCT-00097591.), performed in patients (n=13,608) with moderate-to high-risk ACS undergoing PCI with a follow-up period of 14.5 months. 65 In the overall population, prasugrel therapy was associated with a significant reduction in the rates of the primary end point (composite of cardiovascular death, non-fatal MI or non-fatal stroke) (9.9% vs. 12.1%; HR=0.81; p<0.001), as well as with decreased rates of stent thrombosis. 66 This benefit was hampered by an increased risk of TIMI major non-coronary artery bypass grafting (CABG) related bleeding in the prasugrel group. Considering together ischaemic and bleeding outcomes, no net clinical benefit was found in older patients (≥75 years) and in those weighing less than 60 kg, and even a net clinical harm was observed in patients with a history of stroke or transient ischaemic attack. 65 A predefined subgroup analysis according to DM status suggested a preferential benefit of prasugrel in the DM population ( Figure 1 ). 67 The primary end point was reduced significantly with prasugrel among patients with DM (12.2% vs. 17.0%; HR=0.70; p<0.001), this benefit being consistent in patients receiving insulin (14.3% vs. 22.2%; HR=0.63; p=0.009) and in those not on insulin therapy (11.5% vs. 15.3%; HR=0.74; p=0.009). Overall, major bleeding was higher in DM patients, but remarkably, there was no increase in major bleeding rates Overall, these findings suggest that higher platelet inhibition is associated with improved outcome in DM patients. The pharmacodynamic benefit of prasugrel was recently observed in the Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3; NCT00642174) study, in which a standard prasugrel dose (60 mg loading dose followed by 10 mg maintenance dose daily for 1 week) achieved significantly higher platelet inhibition and better response profiles compared with high-dose clopidogrel (600 mg loading dose followed by 150 mg maintenance dose) in DM patients with CAD on chronic aspirin therapy. 68 The ongoing trial TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage ACS. (TRILOGY ACS; NCT00699998) will provide insights into the clinical efficacy of prasugrel in medically managed patients with NSTEACS, which will likely comprise a large number of DM subjects.
Glycoprotein IIb/IIIa inhibitors
Three GP IIb/IIIa antagonists are available for clinical use: abciximab, eptifibatide and tirofiban. All of them are administered intravenously, have a rapid onset of action, a potent inhibitory effect on platelets and a relatively short half-life. The GP IIb/IIIa receptor is the main mediator of platelet aggregation through its binding to fibrinogen. 8 The efficacy of GP IIb/IIIa blockers correlates directly with the severity and the risk of ACS, hence, using these drugs in low-moderate risk patients or in those managed with a conservative approach is generally not recommended. 69 Therefore, GP IIb/IIIa inhibitors are used mainly in clinical practice as an adjunctive therapy on top of aspirin and a thienopyridine for the acute phase of therapy, due to its intravenous administration, in high-risk ACS patients undergoing PCI.
The efficacy of GP IIb/IIIa inhibitors in the ACS scenario was evaluated in a metaanalysis of six large-scale trials. 70 The use of GP IIb/IIIa blockers was associated with a 26% reduction in 30-day mortality (4.6% vs. 6.2%; p=0.007) in patients with DM (n=6,458), while non-DM patients (n=23,072) had no survival benefit. A statistically significant interaction between treatment with GP IIb/IIIa and DM status was observed. In this metaanalysis, the mortality reduction among DM patients was of greater magnitude in those patients (n=1,279) undergoing PCI during index hospitalisation (4.0-1.2%; p=0.002). 70 However, caution on the conclusions from these study findings is warranted as these may not necessarily apply to today's clinical practice since clopidogrel regimens commonly used in current practice were not used in these trials (e.g. pre-treatment, high loading dose regimens).
Two more recent studies have evaluated the efficacy of GP IIb/IIIa blockers on top of dual antiplatelet therapy. The Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) trial did not show a benefit of abciximab over placebo in terms of reducing the 1-year risk of death and MI in DM patients (n=701) undergoing elective PCI after pre-treatment with a clopidogrel loading dose of 600 mg at least 2 h before the procedure. 71 Conversely, in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) trial, which compared abciximab treatment to placebo in patients with high-risk ACS undergoing PCI after pre-treatment with 600 mg of clopidogrel, a 25% reduction of the risk of adverse events (death, MI or urgent target vessel revascularisation within 30 days) was observed in the abciximab group. 72 Of note, the benefit provided by abciximab was restricted to patients with elevated troponin levels and was observed across all subgroups, including DM patients. Overall, the results of the last two trials performed in the clopidogrel era support the use of GP IIb/IIIa receptor antagonists in high-risk ACS patients undergoing PCI, in particular those with DM, but not for routine use in elective PCI.
The value of GP IIb/IIIa inhibitors in DM patients with STEMI undergoing PCI has been assessed in a few smallscale studies. In a small placebo-controlled randomised study performed before the clopidogrel era, abciximab use was associated with lower mortality and reinfarction rates across the DM subgroup (n=54) in patients undergoing primary coronary stenting for the treatment of acute MI. 73 In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, no benefit was observed with abciximab in a cohort of lowrisk DM patients (n=346) with acute MI treated with balloon angioplasty or stenting. 21 However, a metaregression of randomised trials evaluating the effect of adjunctive use of any GP IIb/IIIa inhibitor (abciximab, eptifibatide and tirofiban) on top of dual antiplatelet therapy in STEMI patients undergoing primary PCI found a relationship between benefit in terms of mortality of these agents and patient's risk profile. 74 Thus, the use of GP IIb/IIIa inhibitors should be considered in high-risk patients undergoing primary PCI, which may include those with DM.
The main drawback associated with the administration of GP IIb/IIIa inhibitors is an increased risk of bleeding, which impairs the prognosis of patients suffering from ACS, even in terms of mortality. 75, 76 A valid alternative may be bivalirudin, a direct thrombin inhibitor, which was shown in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY; NCT00093158) trial to have similar efficacy in reducing ischaemic events and a better safety profile with lower rates of major bleeding compared to GP IIb/IIIa antagonists in moderate-risk NSTEACS patients (n=13,819). 77 In the DM subgroup (n=3,852), bivalirudin therapy was associated with a lower risk of major bleeding (3.7% vs. 7.1%; p<0.001) and similar efficacy in terms of ischaemic outcomes (death, MI or unplanned ischaemic revascularisation) when compared to GP IIb/IIIa plus heparin (7.9% vs. 8.9%; p=0.39). 78 Recently, bivalirudin monotherapy was observed to have similar protection for ischaemic events and lower in-hospital bleeds (mainly minor) in a cohort of patients with DM undergoing elective PCI when compared to combined therapy with unfractionated heparin and tirofiban. 79 Overall, the reduction of bleeding risk with bivalirudin is noteworthy, as DM is a strong predictor of bleeding in ACS and/or PCI patients. 80
Limitations of oral antiplatelet drugs in patients with DM
The relationship between variability in response to antiplatelet therapy and clinical outcomes has been repeatedly and consistently reported, suggesting that poor responsiveness to oral antiplatelet drugs may play an important role in the risk of developing adverse events. 16, 81, 82 The risk of recurrent ischaemic events is higher in DM patients, [18] [19] [20] [21] hence, understanding antiplatelet drug response in this high-risk population is of particular interest.
A number of clinical studies have observed an association between aspirin resistance and a higher risk of recurrent ischaemic events. 83, 84 The prevalence of aspirin resistance varies widely among studies, due mainly to differences in the tests used, definition of resistance, aspirin dosage and population considered. In fact, aspirin resistance is a sporadic phenomenon (<5% of patients) when COX-1 specific assays (e.g. determination of plasmatic or urinary TXA 2 metabolites, tests using arachidonic acid as agonist) are used. 85, 86 Conversely, the prevalence of aspirin resistance is higher when using COX-1 non-specific assays, suggesting that these results are derived not only from COX-1 degree of inhibition, but also from aspirin-induced COX-1-independent effects. 81 Among the factors causing aspirin resistance assessed by COX-1 specific tests, poor patient compliance is the most important and population selection also contributes to the inadequate response. 86 Importantly, reduced response to aspirin has been observed in DM patients with poor metabolic control. 87 Increasing the dose of aspirin has been suggested to overcome resistance in DM patients, who have high rates of impaired response to aspirin, if assessed by COX-1 non-specific methods. 12, 88 A subanalysis of the Aspirin-Induced Platelet Effect (ASPECT) study, which compared the pharmacodynamic effect of different doses of aspirin in patients with and without DM, showed a higher percentage of aspirin resistance in the DM subgroup with the lower dose (81 mg daily). However, increasing the aspirin dose (162 and 325 mg daily) augmented platelet inhibition in patients with DM to an extent that the final rates of aspirin resistance were similar in both groups. 89 To date, few studies have investigated the specific mechanisms of aspirin resistance that are characteristic of DM patients. Some of the mechanisms that have been proposed include the following: (a) hyperglycaemia, as augmented protein glycation may be associated with decreased aspirinmediated protein acetylation; (b) increased TXA 2 synthesis, which is associated with a poor metabolic control; 90 and (c) accelerated platelet turnover, due to the fact that introduction into the bloodstream of newly generated platelets not exposed to aspirin may continue to generate TXA 2 , thereby activating the TP receptor despite COX-1 inhibition. 91 Clopidogrel is the most used thienopyridine and with which there is most laboratory and clinical experience. Despite the undisputed clinical benefit of clopidogrel in addition to aspirin, the number of recurrent cardiovascular events is still relatively high. 18, [57] [58] [59] [60] [61] Variability in individual response to clopidogrel has been consistently associated with this limited efficacy. 16, 17 Genetic, cellular and clinical factors have been proposed to be involved in this variability. The prevalence of clopidogrel low responsiveness varies widely (5-40%) and depends on differences in the type of assays used, the definition of resistance, dosage and the patient population being evaluated. 16, 17 Among the clinical factors, the presence of DM has been repeatedly associated with impaired clopidogrel-induced platelet inhibition both in the acute and maintenance phases of therapy. 12, 14, 15, 92 Of note, DM patients with poor metabolic control and those who require insulin therapy have the worst response to clopidogrel in patients on dual antiplatelet therapy ( Figure 2) . 93, 94 In addition, patients with DM are at a higher risk of developing chronic kidney disease (CKD), which impairs response to antiplatelet agents and is a risk factor per se of worse clinical outcomes. Among DM patients, the presence of moderate to severe CKD is associated with decreased response to clopidogrel, 95 which is in line with the results of a post hoc analysis of the CHARISMA trial, which suggests that clopidogrel use might increase adverse outcomes in patients with diabetic nephropathy. 96 These results contribute overall to clarify why the presence of DM is a strong predictor of recurrent ischaemic events, including stent thrombosis. 97 Several mechanisms have been involved in the impaired clopidogrel-induced effects observed in DM patients, such as: (a) diminished platelet response to insulin; 98 (b) dysregulation of calcium metabolism; 99 (c) upregulation of P2Y 12 receptor signalling; 98 (d) increased exposure to ADP; 100 and (e) increased platelet turnover. 101
Future strategies
The persistence of high platelet reactivity despite the use of standard recommended antiplatelet treatment regimens has led to developing treatment strategies to optimise platelet inhibitory effects, which are of special interest in high-risk subjects such as those with DM. These new approaches can be summarised as follows: (a) increased dosing of currently approved agents; (b) use of new agents; and (c) addition of a third antiplatelet drug. In this section, we provide a brief overview of the studies that have evaluated the above-mentioned strategies in patients with DM.
Currently, the approved loading and maintenance doses for clopidogrel are 300 mg and 75 mg/daily, respectively, although a loading dose of 600 mg is common in clinical practice, especially in patients undergoing PCI. The pharmacodynamic efficacy of a high (150 mg) versus standard maintenance dose of clopidogrel (75 mg) in type 2 DM patients with CAD and high platelet reactivity, while in their maintenance phase of clopidogrel therapy, was evaluated in the OPTIMUS study. Patients randomised to the 150 mg dose showed a marked improvement in platelet inhibition, although a considerable number of patients remained with high platelet reactivity. 102 Results of the CURRENT/OASIS7 trial, which randomised ACS patients in a 2 � 2 factorial design to high (600 mg loading dose followed by 150 mg daily for 1 week and then 75 mg/daily until day 30) or standard dose of clopidogrel (300 mg loading followed by 75 mg daily until day 30) for a month and in an open-label way to high (300-325 mg daily) versus low dose (75-100 mg daily) of aspirin, in which no particular benefit was observed in patients with DM, have been commented on previously. 49 Increasing clopidogrel dosing according to the degree of responsiveness of a given patient, which has been defined as 'tailored' or 'individualised' treatment, has also raised considerable interest. The ongoing Gauging Responsiveness with a VerifyNow Assay-Impact on Thrombosis And Safety (GRAVITAS; NCT00645918) trial will evaluate the efficacy and safety of tailored treatment with high clopidogrel maintenance dose for 6 months in those patients with low response to standard clopidogrel dose in which a considerable number of patients with DM will be enrolled. 103 Several new agents that block multiple pathways involved in platelet adhesion, activation and aggregation are currently at different stages of clinical development. Novel agents targeting the TXA 2 pathway include picotamide (a combined TXA 2 synthase inhibitor and TP receptor blocker), ridogrel (a combined TXA 2 synthase inhibitor and TP receptor blocker), ramatroban (a TP receptor inhibitor), NCX 4016 [a nitric oxide (NO)-releasing aspirin derivative] and S18886/ terutroban (a TP receptor inhibitor). These have been evaluated in different scenarios with variable success and might be of future interest, although none of them appear to be suitable for replacing aspirin at the current time. [104] [105] [106] [107] [108] Novel and more potent P2Y 12 receptor inhibitors (prasugrel, ticagrelor, cangrelor, elinogrel) have emerged recently and may represent attractive treatment choices in high-risk patients, such as those with DM. The pharmacodynamic effects of the third-generation thienopyridine prasugrel and its beneficial clinical implications specifically in patients with DM have already been discussed in this manuscript. Ticagrelor is an orally administered cyclopentyltriazolopyrimidine, which directly and reversibly inhibits the platelet ADP P2Y 12 receptor. 109, 110 Ticagrelor has a faster onset and offset of action and achieves higher inhibition of platelet aggregation than clopidogrel. 111, 112 The phase III Study of Platelet Inhibition and Patient Outcomes (PLATO) trial randomised ACS patients (n=18,624) to receive either ticagrelor (180 mg loading dose followed by 90 mg twice daily) or clopidogrel (300-600 mg loading dose followed by 75 mg daily). The rate of the primary end point (death from vascular causes, MI or stroke) at 12 months was significantly decreased in the ticagrelor arm (10.2% vs. 12.3%; HR=0.84; p=0.0001), as well as, remarkably, the rate of cardiovascular death (4.0% vs. 5.1%; HR=0.79; p=0.001) and the occurrence of definite or probable stent thrombosis (2.2% vs. 2.9%; HR=0.75; p=0.02) in the subgroup of patients undergoing PCI. This benefit was not hampered by an increase in protocol-defined major bleeding (11.6% vs. 11.2%; HR=1.04; p=0.43), although ticagrelor use was associated with a higher rate of major bleeding not related to CABG (4.5% vs. 3.8%; HR=1.19; p=0.03). 113 A predefined subgroup analysis of the DM cohort (n=4,662) showed a nonsignificant reduction of the rates of the primary end point [14. 1% vs. 16.2%; HR=0.88 (0.76-1.03)], while no difference in major bleeding rates was found [14. 1% vs. 14.8%; HR=0.95 (0.81-1.12)]. Ticagrelor is currently pending approval by regulatory authorities for clinical use.
Cangrelor is an intravenous ATP analogue, which is a direct-acting, reversible, without any biotransformation, P2Y 12 receptor inhibitor. 109, 114 Phase II trials showed promising results, as cangrelor proved to be a very potent antiplatelet agent, achieving >90% inhibition of platelet aggregation, with very rapid onset and offset of action, as well as dose-dependent and, thus, predictable, effects. 115 However, the results of the phase III Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) program, which evaluated mostly ACS patients undergoing PCI, failed to show the superiority of cangrelor over clopidogrel in the CHAMPION-PCI (NCT00305162) (n=8,716), and over placebo in the CHAMPION-PLATFORM (NCT00385138) (n=5,362) in terms of reducing ischaemic outcomes. 116, 117 Analysis of the DM cohort (n=2,702) from the CHAMPION-PCI trial showed results that were consistent with those obtained in the overall population.
Elinogrel is a novel, direct-acting and reversible P2Y 12 inhibitor in the preliminary stages of development, with the important feature of having both oral and intravenous ways of administration. 118, 119 The ongoing trial INtraveNous and Oral administration of elinogrel to eVAluate Tolerability and Efficacy in nonurgent PCI patients (INNOVATE-PCI). (INNOVATE-PCI; NCT00751231) is evaluating the efficacy and safety of three different doses of elinogrel (oral 50, 100 and 150 mg twice daily following an intravenous bolus) in patients undergoing non-urgent PCI. 120 Future strategies also include the use of a third antiplatelet drug that blocks pathways other than COX-1 and P2Y 12 to be used on top of aspirin and a P2Y 12 inhibitor. Drugs that have been proposed for being part of such 'triple therapy' are: (a) cilostazol; (b) protease-activated receptor-1 (PAR-1) antagonists; and (c) new oral anticoagulants. Among them, cilostazol, a phosphodiesterase III inhibitor that increases intraplatelet cyclic adenosine monophosphate (cAMP) concentration, has the most consistent data reporting a benefit in patients with DM. In patients with type 2 DM, the OPTIMUS-2 study showed that adjunctive use of cilostazol on top of standard dual antiplatelet therapy increases platelet inhibition. 121 This enhanced platelet inhibitory effect may contribute to the better outcomes observed in patients undergoing PCI, both elective and after suffering an ACS event. [122] [123] [124] Interestingly, this benefit appears to be higher in high-risk patients, such as those with DM, and seems not to be hampered by an increase in bleeding. 125, 126 The high frequency of side effects (mainly headache, palpitations and gastrointestinal disturbances) may, however, limit the use of cilostazol. 121 Two oral thrombin receptor antagonists, which block the platelet PAR-1 receptor subtype, are currently under clinical development: vorapaxar (SCH 530348) and E5555 (Figure 3 ). 109, 127, 128 Vorapaxar has shown an excellent safety profile in a large, phase II safety and dose-ranging trial performed in patients (n=1,030) undergoing non-urgent PCI or coronary angiography with planned PCI, in which triple therapy was not associated with any significant increase of bleeding across all doses tested. 129 130, 131 Finally, several new oral anticoagulants are currently under investigation and being tested in adjunct to standard antiplatelet treatment regimens in high-risk settings. In fact, in high-risk settings such as patients with ACS, in addition to increased platelet reactivity, dysregulation of coagulation processes may also occur and contribute to atherothrombotic recurrences. Novel oral anticoagulants include anti-factor IIa or 'gatrans' (e.g. dabigatran) and anti-factor Xa or 'xabans' (e.g. rivaroxaban, apixaban), which are currently at different stages of development. 132
Conclusions
Patients with DM have higher rates of adverse cardiovascular events compared with those without DM despite using recommended antiplatelet treatment regimens. A high prevalence of impaired response to standard antiplatelet therapies is characteristic of DM, which may contribute to their worse outcomes. Therefore, more potent antiplatelet therapy is needed in such a high-risk population. Novel antiplatelet treatment strategies that are currently under investigation will provide important insights on their safety and efficacy in high-risk settings, including patients with DM.
Funding
This work was supported by an unrestricted educational grant from Eli Lilly and Daiichi Sankyo to the University of Sheffield to fund the activities of the European Platelet Academy.
Conflicts of interest
José Luis Ferreiro and Ángel R Cequier have no conflicts of interest to report. Dominick J Angiolillo reports receiving honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company and Daiichi Sankyo, Inc.; consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Daiichi Sankyo, Inc., The Medicines Company, Portola Pharmaceuticals Inc., Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, Inc., AstraZeneca and Merck & Co., Inc.; and research grants from GlaxoSmithKline, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Daiichi Sankyo, Inc., The Medicines Company, Portola Pharmaceuticals Inc., Accumetrics, Schering-Plough, AstraZeneca and Eisai. Platelet adhesion is mediated by GP receptors, which bind to exposed extracellular matrix proteins (collagen and vWF). Several intracellular signalling pathways contribute to platelet activation, which causes local production of thrombin and the production and release of multiple agonists, including TXA 2 and ADP. These factors bind to G protein-coupled receptors, inducing paracrine and autocrine mechanisms, as well as potentiating each other's actions (e.g. P2Y 12 signalling modulates thrombin generation). The integrin GP IIb/IIIa complex mediates the final common step of platelet activation by undergoing a conformational shape change and binding fibrinogen and vWF, which leads to platelet aggregation. The final result of these processes is thrombus formation due to platelet/ platelet interactions with fibrin. Current and emerging agents inhibiting platelet receptors, integrins and proteins involved in this process include TX inhibitors, ADP receptor antagonists, GP inhibitors, adhesion antagonists and PAR antagonists. Reversible agents are indicated by brackets.
Source: Reprinted from Angiolillo DJ, Capodanno D and Goto S. Platelet thrombin receptor antagonism and atherothrombosis. 128 European Heart Journal, 31: 17-28 (2010), with permission from Oxford University Press. 5-HT2A: 5-hydroxytryptamine 2A receptor, ADP: adenosine diphosphate, COX-1: cyclooxygenase-1, GP: glycoprotein, PAR: protease-activated receptor, TP: thromboxane/prostaglandin endoperoxide receptors, TX: thromboxane, TXA2: thromboxane A 2 , vWF: von Willebrand factor.
